Trial · NCT04157348
Adverse events264
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 264
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctivitis | Infections and infestations | Benra 30 mg - DB | 2 | 70 | 2 |
| other | Conjunctivitis | Infections and infestations | Mepo 300 mg - DB | 1 | 70 | 1 |
| other | Conjunctivitis | Infections and infestations | Benra 30 mg - OLE | 1 | 66 | 1 |
| other | Conjunctivitis | Infections and infestations | Mepo 300 mg Switched to Benra 30 mg - OLE | 4 | 62 | 4 |
| other | Bronchitis | Infections and infestations | Benra 30 mg - DB | 4 | 70 | 4 |
| other | Bronchitis | Infections and infestations | Mepo 300 mg - DB | 5 | 70 | 8 |
| other | Bronchitis | Infections and infestations | Benra 30 mg - OLE | 7 | 66 | 9 |
| other | Bronchitis | Infections and infestations | Mepo 300 mg Switched to Benra 30 mg - OLE | 2 | 62 | 3 |
| other | COVID-19 | Infections and infestations | Benra 30 mg - DB | 14 | 70 | 14 |
| other | COVID-19 | Infections and infestations | Mepo 300 mg - DB | 18 | 70 | 18 |
| other | COVID-19 | Infections and infestations | Benra 30 mg - OLE | 22 | 66 | 25 |
| other | COVID-19 | Infections and infestations | Mepo 300 mg Switched to Benra 30 mg - OLE | 27 | 62 | 30 |
| other | Nasopharyngitis | Infections and infestations | Benra 30 mg - DB | 6 | 70 | 6 |
| other | Nasopharyngitis | Infections and infestations | Mepo 300 mg - DB | 10 | 70 | 12 |
| other | Nasopharyngitis | Infections and infestations | Benra 30 mg - OLE | 6 | 66 | 7 |
| other | Nasopharyngitis | Infections and infestations | Mepo 300 mg Switched to Benra 30 mg - OLE | 11 | 62 | 19 |
| other | Oral candidiasis | Infections and infestations | Benra 30 mg - DB | 2 | 70 | 2 |
| other | Oral candidiasis | Infections and infestations | Mepo 300 mg - DB | 4 | 70 | 4 |
| other | Oral candidiasis | Infections and infestations | Benra 30 mg - OLE | 2 | 66 | 2 |
| other | Oral candidiasis | Infections and infestations | Mepo 300 mg Switched to Benra 30 mg - OLE | 2 | 62 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04157348/events